Archean Chemical Industries Limited — Q4 FY26
Archean Chemical's Q4 FY26 standalone revenue fell 9% YoY to ₹304.7 crore, with EBITDA down 34.3% to ₹66.4 crore and margin at 21.79%.
bearish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
SOP plant-scale trials in Q4 FY26, meaningful contribution in H2 FY27
SOP pilot trials successful; plant-scale trials to commence in Q4 FY26, with meaningful revenue expected in second half of FY27.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1